GlassScriptPhysician profile
David R Rittenhouse
NPI 1811950397
$11,257.19
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,238 · 2020: $1,635 · 2021: $2,065 · 2022: $2,238 · 2023: $2,040 · 2024: $41.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.73 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,719.50 | 2019-2023 | Xtandi, Myrbetriq, Veozah |
| Coloplast Corp | $1,706.20 | 2019-2023 | Titan, Altis |
| Janssen Biotech, INC. | $1,058.83 | 2019-2023 | Erleada |
| Medtronic USA, INC. | $916.31 | 2019-2020 | |
| Boston Scientific Corporation | $598.43 | 2019-2022 | |
| Medtronic, INC. | $393.21 | 2021-2023 | Interstim |
| Myriad Genetic Laboratories, INC. | $383.26 | 2022-2023 | Prolaris |
| Pfizer INC. | $339.77 | 2019-2023 | |
| Myovant Sciences INC. | $293.46 | 2021-2022 | |
| Abbvie INC. | $292.26 | 2019-2023 | Lupron Depot |
| Axonics, INC. | $261.38 | 2020-2023 | Axonics, Bulkamid |
| Innovation Technologies INC | $248.39 | 2022-2023 | Irrisept |
| Teleflex LLC | $240.82 | 2022-2023 | Urolift |
| Antares Pharma, INC. | $222.95 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Dendreon Pharmaceuticals LLC | $197.54 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rittenhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.